159 related articles for article (PubMed ID: 9466464)
1. Cholecystokinin inhibits peripheral opioid analgesia in inflamed tissue.
Schäfer M; Zhou L; Stein C
Neuroscience; 1998 Jan; 82(2):603-11. PubMed ID: 9466464
[TBL] [Abstract][Full Text] [Related]
2. Contribution of opioid receptors on primary afferent versus sympathetic neurons to peripheral opioid analgesia.
Zhou L; Zhang Q; Stein C; Schäfer M
J Pharmacol Exp Ther; 1998 Aug; 286(2):1000-6. PubMed ID: 9694961
[TBL] [Abstract][Full Text] [Related]
3. Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists.
Noble F; Smadja C; Roques BP
J Pharmacol Exp Ther; 1994 Dec; 271(3):1127-34. PubMed ID: 7996417
[TBL] [Abstract][Full Text] [Related]
4. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors.
Stein C; Millan MJ; Shippenberg TS; Peter K; Herz A
J Pharmacol Exp Ther; 1989 Mar; 248(3):1269-75. PubMed ID: 2539460
[TBL] [Abstract][Full Text] [Related]
5. Possible mechanisms for insulin-induced attenuation of the antinociceptive effect of [D-Ala2, N-MePhe4, Gly-ol5]enkephalin.
Ohsawa M; Tanaka S; Kamei J
Eur J Pharmacol; 1999 Jun; 373(2-3):181-6. PubMed ID: 10414437
[TBL] [Abstract][Full Text] [Related]
6. The antinociceptive action of supraspinal opioids results from an increase in descending inhibitory control: correlation of nociceptive behavior and c-fos expression.
Gogas KR; Presley RW; Levine JD; Basbaum AI
Neuroscience; 1991; 42(3):617-28. PubMed ID: 1659673
[TBL] [Abstract][Full Text] [Related]
7. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of nitric oxide synthase enhances antinociception mediated by mu, delta and kappa opioid receptors in acute and prolonged pain in the rat spinal cord.
Machelska H; Labuz D; Przewłocki R; Przewłocka B
J Pharmacol Exp Ther; 1997 Aug; 282(2):977-84. PubMed ID: 9262366
[TBL] [Abstract][Full Text] [Related]
9. Possible involvement of protein kinase C in the attenuation of [D-Ala2, NMePhe4, Gly-ol5]enkephalin-induced antinociception in diabetic mice.
Ohsawa M; Kamei J
Eur J Pharmacol; 1997 Nov; 339(1):27-31. PubMed ID: 9450613
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase C-mediated acute tolerance to peripheral mu-opioid analgesia in the bradykinin-nociception test in mice.
Inoue M; Ueda H
J Pharmacol Exp Ther; 2000 May; 293(2):662-9. PubMed ID: 10773042
[TBL] [Abstract][Full Text] [Related]
11. Differential modulation of alpha 2-adrenergic and opioid spinal antinociception by cholecystokinin and cholecystokinin antagonists in the rat dorsal horn: an electrophysiological study.
Sullivan AF; Hewett K; Dickenson AH
Brain Res; 1994 Oct; 662(1-2):141-7. PubMed ID: 7859067
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment with protein kinase C activator phorbol 12,13-dibutyrate attenuates the antinociception induced by mu- but not epsilon-opioid receptor agonist in the mouse.
Narita M; Ohsawa M; Mizoguchi H; Kamei J; Tseng LF
Neuroscience; 1997 Jan; 76(1):291-8. PubMed ID: 8971779
[TBL] [Abstract][Full Text] [Related]
13. Antinociceptive effects of dynorphin peptides in a model of inflammatory pain.
Beyer A; Schäfer M; Stein C
Pain; 1997 Apr; 70(2-3):141-7. PubMed ID: 9150287
[TBL] [Abstract][Full Text] [Related]
14. Intraventricular insulin reduces the antinociceptive effect of [D-Ala2, NMePhe4, Gly-ol5]enkephalin in mice.
Kamei J; Ohsawa M; Sodeyama M; Kimura M; Tanaka S
Eur J Pharmacol; 1998 Mar; 345(2):171-4. PubMed ID: 9600633
[TBL] [Abstract][Full Text] [Related]
15. Dynorphinergic mechanism mediating endomorphin-2-induced antianalgesia in the mouse spinal cord.
Wu HE; Sun HS; Darpolar M; Leitermann RJ; Kampine JP; Tseng LF
J Pharmacol Exp Ther; 2003 Dec; 307(3):1135-41. PubMed ID: 14557378
[TBL] [Abstract][Full Text] [Related]
16. Nonopioidergic mechanism mediating morphine-induced antianalgesia in the mouse spinal cord.
Wu HE; Thompson J; Sun HS; Leitermann RJ; Fujimoto JM; Tseng LF
J Pharmacol Exp Ther; 2004 Jul; 310(1):240-6. PubMed ID: 14999057
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of intrathecally administered delta and mu opioid receptor agonists on formalin-evoked nociception and on the expression of Fos-like immunoreactivity in the spinal cord of the rat.
Hammond DL; Wang H; Nakashima N; Basbaum AI
J Pharmacol Exp Ther; 1998 Jan; 284(1):378-87. PubMed ID: 9435201
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of spinal opioid analgesia by supraspinal administration of selective opioid antagonists.
Miaskowski C; Levine JD
Brain Res; 1992 Nov; 596(1-2):41-5. PubMed ID: 1361418
[TBL] [Abstract][Full Text] [Related]
19. Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neuropathic pain in rats.
Nichols ML; Bian D; Ossipov MH; Lai J; Porreca F
J Pharmacol Exp Ther; 1995 Dec; 275(3):1339-45. PubMed ID: 8531101
[TBL] [Abstract][Full Text] [Related]
20. Peripheral antinociceptive effects of exogenous and immune cell-derived endomorphins in prolonged inflammatory pain.
Labuz D; Berger S; Mousa SA; Zöllner C; Rittner HL; Shaqura MA; Segovia-Silvestre T; Przewlocka B; Stein C; Machelska H
J Neurosci; 2006 Apr; 26(16):4350-8. PubMed ID: 16624955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
